rituximab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
chimeric origin	4975	174722-31-7

Description:

Molecule	Description
Synonyms: rituximab rituxan MabThera rituximab (genetical recombination)	A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

rituximab
rituxan
MabThera
rituximab (genetical recombination)

A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Show entries

Search:

Date	Agency	Company
Jan. 25, 2008	PMDA	Bayer Yakuhin, Nihon Schering, Zenyaku Kogyo
June 2, 1998	EMA	Roche Registration GmbH
Nov. 26, 1997	FDA	GENENTECH

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	2963.06	11.89	15033	441958	1029732	62002299
Contraindicated product administered	2927.71	11.89	5450	451541	212198	62819833
Drug intolerance	2402.02	11.89	6200	450791	302461	62729570
Treatment failure	2194.37	11.89	4587	452404	194456	62837575
Pemphigus	2136.94	11.89	4329	452662	179397	62852634
Infusion related reaction	2014.54	11.89	5034	451957	240487	62791544
Off label use	2007.93	11.89	9859	447132	664603	62367428
Systemic lupus erythematosus	1995.93	11.89	4545	452446	204373	62827658
Glossodynia	1723.88	11.89	3906	453085	174970	62857061
Synovitis	1602.17	11.89	3899	453092	183019	62849012

Showing 1 to 10 of 1,169 entries

Previous1 2 3 4 5…117Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Off label use	2381.48	11.80	5936	168757	413588	34368650
Febrile neutropenia	1436.65	11.80	2502	172191	134347	34647891
Disease progression	1098.00	11.80	1949	172744	106128	34676110
Progressive multifocal leukoencephalopathy	972.88	11.80	607	174086	9157	34773081
Neutropenia	904.81	11.80	2242	172451	154536	34627702
Intentional product use issue	756.60	11.80	1191	173502	58625	34723613
Hypogammaglobulinaemia	725.55	11.80	463	174230	7277	34774961
Diffuse large B-cell lymphoma recurrent	703.67	11.80	337	174356	2891	34779347
Hepatitis B	691.21	11.80	409	174284	5574	34776664
Infusion related reaction	674.46	11.80	1059	173634	51998	34730240

Showing 1 to 10 of 827 entries

Previous1 2 3 4 5…83Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Off label use	3175.82	10.99	12535	482438	894680	78354735
Drug ineffective	2536.03	10.99	13273	481700	1067640	78181775
Infusion related reaction	2407.66	10.99	4760	490213	225477	79023938
Drug intolerance	2176.16	10.99	4955	490018	259164	78990251
Contraindicated product administered	2054.65	10.99	3583	491390	153955	79095460
Treatment failure	1804.04	10.99	3544	491429	166942	79082473
Synovitis	1593.90	10.99	3133	491840	147601	79101814
Progressive multifocal leukoencephalopathy	1483.01	10.99	1140	493833	19460	79229955
Joint swelling	1456.36	10.99	4514	490459	284132	78965283
Completed suicide	1434.33	10.99	17	494956	245750	79003665

Showing 1 to 10 of 1,393 entries

Previous1 2 3 4 5…140Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01FA01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES CD20 (Clusters of Differentiation 20) inhibitors
FDA EPC	N0000175657	CD20-directed Cytolytic Antibody
FDA MoA	N0000175078	CD20-directed Antibody Interactions
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000074322	Antineoplastic Agents, Immunological
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D007155	Immunologic Factors

Showing 1 to 7 of 7 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Burkitt cell leukemia	indication	22197008
Neuromyelitis optica	indication	25044007	DOID:8869
Pemphigus foliaceus	indication	35154004
Pemphigus vulgaris	indication	49420001	DOID:0060851
Follicular lymphoma	indication	55150002
Rheumatoid arthritis	indication	69896004	DOID:7148
Burkitt's lymphoma	indication	77381001	DOID:8584
Thrombotic thrombocytopenic purpura	indication	78129009	DOID:10772
Systemic sclerosis	indication	89155008	DOID:418
Chronic lymphoid leukemia, disease	indication	92814006

Showing 1 to 10 of 15 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
B-lymphocyte antigen CD20	Surface antigen	P11836	CD20_HUMAN	ANTIBODY BINDING	Kd	8.51		IUPHAR	DRUG LABEL

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
007236	NDDF
108809004	SNOMEDCT_US
11468	MMSL
121191	RXNORM
386919002	SNOMEDCT_US
4021104	VUID
4021104	VANDF
4F4X42SYQ6	UNII
5432	MMSL
6780	IUPHAR_LIGAND_ID

Showing 1 to 10 of 18 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Riabni	HUMAN PRESCRIPTION DRUG LABEL	1	55513-224	INJECTION, SOLUTION	100 mg	INTRAVENOUS	BLA	32 sections
Riabni	HUMAN PRESCRIPTION DRUG LABEL	1	55513-224	INJECTION, SOLUTION	100 mg	INTRAVENOUS	BLA	32 sections
Riabni	HUMAN PRESCRIPTION DRUG LABEL	1	55513-326	INJECTION, SOLUTION	500 mg	INTRAVENOUS	BLA	32 sections
Riabni	HUMAN PRESCRIPTION DRUG LABEL	1	55513-326	INJECTION, SOLUTION	500 mg	INTRAVENOUS	BLA	32 sections
Rituxan	HUMAN PRESCRIPTION DRUG LABEL	1	50242-051	INJECTION, SOLUTION	10 mg	INTRAVENOUS	BLA	32 sections
Rituxan	HUMAN PRESCRIPTION DRUG LABEL	1	50242-051	INJECTION, SOLUTION	10 mg	INTRAVENOUS	BLA	32 sections
Rituxan	HUMAN PRESCRIPTION DRUG LABEL	1	50242-051	INJECTION, SOLUTION	10 mg	INTRAVENOUS	BLA	32 sections
Rituxan	HUMAN PRESCRIPTION DRUG LABEL	1	50242-053	INJECTION, SOLUTION	10 mg	INTRAVENOUS	BLA	32 sections
Rituxan	HUMAN PRESCRIPTION DRUG LABEL	1	50242-053	INJECTION, SOLUTION	10 mg	INTRAVENOUS	BLA	32 sections
Rituxan	HUMAN PRESCRIPTION DRUG LABEL	1	50242-053	INJECTION, SOLUTION	10 mg	INTRAVENOUS	BLA	32 sections

Showing 1 to 10 of 22 entries

Previous1 2 3Next